HRP20161634T1 - Novi pripravak alfentanila za liječenje akutne boli - Google Patents
Novi pripravak alfentanila za liječenje akutne boli Download PDFInfo
- Publication number
- HRP20161634T1 HRP20161634T1 HRP20161634TT HRP20161634T HRP20161634T1 HR P20161634 T1 HRP20161634 T1 HR P20161634T1 HR P20161634T T HRP20161634T T HR P20161634TT HR P20161634 T HRP20161634 T HR P20161634T HR P20161634 T1 HRP20161634 T1 HR P20161634T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- alfentanil
- preparation according
- carrier particles
- administration
- Prior art date
Links
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 title claims 7
- 229960001391 alfentanil Drugs 0.000 title claims 7
- 208000002193 Pain Diseases 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 6
- 208000005298 acute pain Diseases 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims 1
- 235000019801 trisodium phosphate Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Farmaceutski pripravak pogodan za sublingvalnu isporuku, kao i za brzo oslobađanje alfentanila iz njega i/ili brzo uzimanje alfentanila kroz sluznicu usta, koji sadrži smjesu naznačenu time da sadrži:
(a) mikročestice alfentanila, ili njegove farmaceutski prihvatljive soli, te su navedene mikročestice iskazane na površinama većih čestica nosača;
(b) slabu bazu; i
(c) spoj koji je slaba kiselina, te je navedena kiselina predstavljena u bliskoj smjesi s mikročesticama alfentanila ili njegovom soli, tako što se nalazi bilo:
(1) unutar čestica nosača, tako da navedene čestice nosača sadrže kompozit od:
(i) navedenog kiselog materijala; i
(ii) drugog materijala čestica nosača; ili
(2) na površinama čestica nosača.
2. Pripravak prema zahtjevu 1, naznačen time da kiselina je limunska kiselina.
3. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da slaba baza sadrži fosfat.
4. Pripravak prema zahtjevu 3, naznačen time da slaba baza je trinatrijev fosfat.
5. Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da čestice nosača sadrže manitol.
6. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da dodatno sadrži sredstvo za razgradnju.
7. Pripravak prema zahtjevu 6, naznačen time da sredstvo za razgradnju je super sredstvo za razgradnju odabrano od natrijeve kroskarmeloze, natrijevog škrobnog glikolata, umreženog polivinilpirolidona ili od njihove smjese.
8. Pripravak prema zahtjevu 1, naznačen time da je baza topiva u vodi.
9. Pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je u obliku tablete prikladne za sublingvalnu primjenu.
10. Postupak za pripremanje pripravka kao što je definirano u bilo kojem od zahtjeva 1 do 9, naznačen time da sadrži suho miješanje čestica nosača s alfentanilom ili njegovom soli.
11. Postupak za pripremanje sublingvalne tablete kao što je definirano u zahtjevu 9, naznačen time da sadrži direktno komprimiranje ili sabijanje pripravka kao što je definirano u bilo kojem od zahtjeva 1 do 8.
12. Pripravak kao što je definirano u bilo kojem od zahtjeva 1 do 9 naznačen time da je za uporabu u postupku liječenja boli.
13. Pripravak za uporabu kao što je definirano u zahtjevu 12, naznačen time da bol je umjerena do jaka bol.
14. Pripravak za uporabu kao što je definirano u zahtjevu 13, naznačen time da je liječenje kratkotrajno.
15. Pripravak za uporabu kao što je definirano u zahtjevu 13 ili zahtjevu 14, naznačen time da je bol povezana sa dijagnostičkim postupkom, kirurškim postupkom ili postupkom povezanim s njegom.
16. Pripravak za uporabu kao što je definirano u zahtjevu 15 naznačen time da se pripravak primjenjuje ne više od oko 20 minuta prije postupka.
17. Pripravak za uporabu kao što je definirano u bilo kojem od zahtjeva 12 do 16, naznačen time da postupak liječenja boli obuhvaća sublingvalnu primjenu pacijentu koji je čovjek kojem je potreban tretman s farmaceutskim pripravkom koji sadrži između oko 30 µg i oko 3,000 µg alfentanila ili njegove farmaceutski prihvatljive soli, pri čemu navedena primjena dovodi do krivulje koncentracija plazme prema vremenu nakon navedene primjene koja ima:
(I) tmax (vrijeme do maksimalne koncentracije u plazmi) koje je između oko 10 i oko 25 minuta nakon navedene primjene; i/ili
(II) tlast (vrijeme do posljednje mjerljive koncentracije u plazmi) koje nije više od oko 300 minuta nakon navedene primjene; te proizvoljno,
(III) Cmax (maksimalna koncentracija u plazmi) koja je između oko 10 i oko 100 ng po mL plazme.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207701.2A GB201207701D0 (en) | 2012-05-02 | 2012-05-02 | New pharmaceutical composition |
| GBGB1221130.6A GB201221130D0 (en) | 2012-11-23 | 2012-11-23 | New pharmaceutical composition |
| PCT/GB2013/051131 WO2013164620A1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
| EP13727314.0A EP2849730B1 (en) | 2012-05-02 | 2013-05-01 | New alfentanil composition for the treatment of acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161634T1 true HRP20161634T1 (hr) | 2017-01-13 |
Family
ID=48577134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161634TT HRP20161634T1 (hr) | 2012-05-02 | 2016-12-05 | Novi pripravak alfentanila za liječenje akutne boli |
| HRP20181761TT HRP20181761T1 (hr) | 2012-05-02 | 2018-10-25 | Novi pripravak alfentanila za liječenje akutne boli |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181761TT HRP20181761T1 (hr) | 2012-05-02 | 2018-10-25 | Novi pripravak alfentanila za liječenje akutne boli |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US8815911B2 (hr) |
| EP (2) | EP2849730B1 (hr) |
| JP (1) | JP6275696B2 (hr) |
| KR (1) | KR20150005695A (hr) |
| CN (1) | CN104427978B (hr) |
| AU (1) | AU2013255640B2 (hr) |
| BR (1) | BR112014027213A8 (hr) |
| CA (1) | CA2871805A1 (hr) |
| CL (1) | CL2014002979A1 (hr) |
| CO (1) | CO7170181A2 (hr) |
| CY (2) | CY1118570T1 (hr) |
| DK (2) | DK3150199T3 (hr) |
| EA (1) | EA028110B1 (hr) |
| ES (2) | ES2694644T3 (hr) |
| HK (1) | HK1203399A1 (hr) |
| HR (2) | HRP20161634T1 (hr) |
| HU (1) | HUE031792T2 (hr) |
| IL (1) | IL235272B (hr) |
| IN (1) | IN2014MN02156A (hr) |
| LT (2) | LT3150199T (hr) |
| ME (1) | ME02644B (hr) |
| MX (1) | MX360665B (hr) |
| NZ (1) | NZ701428A (hr) |
| PE (1) | PE20142444A1 (hr) |
| PH (1) | PH12014502407B1 (hr) |
| PL (2) | PL2849730T3 (hr) |
| PT (2) | PT3150199T (hr) |
| RS (2) | RS55489B1 (hr) |
| SG (1) | SG11201407081PA (hr) |
| SI (2) | SI3150199T1 (hr) |
| SM (1) | SMT201700086B (hr) |
| TR (1) | TR201815935T4 (hr) |
| WO (1) | WO2013164620A1 (hr) |
| ZA (1) | ZA201407559B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2915525T3 (pl) | 2011-09-19 | 2022-01-17 | Orexo Ab | Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson |
| PL2849730T3 (pl) * | 2012-05-02 | 2017-05-31 | Orexo Ab | Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu |
| US10766925B2 (en) * | 2016-04-11 | 2020-09-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Opioid receptor modulators |
| JP7023054B2 (ja) * | 2017-04-05 | 2022-02-21 | 東和薬品株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| CN115047109B (zh) * | 2022-06-17 | 2024-05-31 | 三明海关综合技术服务中心 | 一种检测食品中芬太尼类新精神活性物质的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| DE19749724A1 (de) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| EP1587514B3 (en) | 2003-01-31 | 2011-06-22 | Orexo AB | A rapid-acting pharmaceutical composition |
| ES2414084T3 (es) | 2003-02-24 | 2013-07-18 | Pharmaceutical Productions Inc. | Sistema de administración de fármacos por vía transmucosa |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| WO2005065319A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| US20070036853A1 (en) | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| AU2004311879B2 (en) | 2003-12-31 | 2010-08-05 | Cima Labs Inc. | Effervescent oral opiate dosage form |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| EP1863456A1 (en) | 2005-03-28 | 2007-12-12 | Orexo AB | New pharmaceutical compositions useful in the treatment of pain |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8535714B2 (en) * | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| US20100233257A1 (en) | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| DK2054031T3 (en) * | 2006-07-21 | 2016-05-17 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with improved uptake |
| JP5484062B2 (ja) * | 2006-12-04 | 2014-05-07 | オレクソ・アクチエボラゲット | オピオイドを含む新規の非−乱用性医薬組成物 |
| EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| KR101606944B1 (ko) | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
| US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
| US8343978B2 (en) | 2008-08-04 | 2013-01-01 | Adds Pharmaceuticals Llc | Fast onset orodispersable tablets |
| US20100056574A1 (en) | 2008-09-04 | 2010-03-04 | Mallinckrodt Inc. | Crystalline Forms of Sufentanil |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| EP2429503A1 (en) | 2009-05-13 | 2012-03-21 | Protein Delivery Solutions, LLC | Pharmaceutical system for trans-membrane delivery |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| JP2009280611A (ja) * | 2009-08-26 | 2009-12-03 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜フィルム剤 |
| US20110091544A1 (en) | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| PL2849730T3 (pl) * | 2012-05-02 | 2017-05-31 | Orexo Ab | Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu |
-
2013
- 2013-05-01 PL PL13727314T patent/PL2849730T3/pl unknown
- 2013-05-01 HU HUE13727314A patent/HUE031792T2/en unknown
- 2013-05-01 CN CN201380022630.2A patent/CN104427978B/zh not_active Expired - Fee Related
- 2013-05-01 PE PE2014001937A patent/PE20142444A1/es not_active Application Discontinuation
- 2013-05-01 ME MEP-2017-9A patent/ME02644B/me unknown
- 2013-05-01 US US13/874,762 patent/US8815911B2/en not_active Expired - Fee Related
- 2013-05-01 EP EP13727314.0A patent/EP2849730B1/en active Active
- 2013-05-01 RS RS20161161A patent/RS55489B1/sr unknown
- 2013-05-01 RS RS20181295A patent/RS57951B1/sr unknown
- 2013-05-01 NZ NZ701428A patent/NZ701428A/en not_active IP Right Cessation
- 2013-05-01 LT LTEP16197166.8T patent/LT3150199T/lt unknown
- 2013-05-01 EP EP16197166.8A patent/EP3150199B1/en active Active
- 2013-05-01 WO PCT/GB2013/051131 patent/WO2013164620A1/en active Application Filing
- 2013-05-01 SI SI201331238T patent/SI3150199T1/sl unknown
- 2013-05-01 PT PT16197166T patent/PT3150199T/pt unknown
- 2013-05-01 ES ES16197166.8T patent/ES2694644T3/es active Active
- 2013-05-01 DK DK16197166.8T patent/DK3150199T3/en active
- 2013-05-01 PL PL16197166T patent/PL3150199T3/pl unknown
- 2013-05-01 PT PT137273140T patent/PT2849730T/pt unknown
- 2013-05-01 CA CA2871805A patent/CA2871805A1/en not_active Abandoned
- 2013-05-01 SI SI201330490A patent/SI2849730T1/sl unknown
- 2013-05-01 KR KR1020147033700A patent/KR20150005695A/ko not_active Application Discontinuation
- 2013-05-01 EA EA201401200A patent/EA028110B1/ru not_active IP Right Cessation
- 2013-05-01 MX MX2014013176A patent/MX360665B/es active IP Right Grant
- 2013-05-01 DK DK13727314.0T patent/DK2849730T3/en active
- 2013-05-01 AU AU2013255640A patent/AU2013255640B2/en not_active Ceased
- 2013-05-01 JP JP2015509496A patent/JP6275696B2/ja not_active Expired - Fee Related
- 2013-05-01 IN IN2156MUN2014 patent/IN2014MN02156A/en unknown
- 2013-05-01 SG SG11201407081PA patent/SG11201407081PA/en unknown
- 2013-05-01 ES ES13727314.0T patent/ES2614757T3/es active Active
- 2013-05-01 LT LTEP13727314.0T patent/LT2849730T/lt unknown
- 2013-05-01 BR BR112014027213A patent/BR112014027213A8/pt not_active Application Discontinuation
- 2013-05-01 TR TR2018/15935T patent/TR201815935T4/tr unknown
-
2014
- 2014-07-15 US US14/331,507 patent/US9345698B2/en not_active Expired - Fee Related
- 2014-10-17 ZA ZA2014/07559A patent/ZA201407559B/en unknown
- 2014-10-22 IL IL235272A patent/IL235272B/en not_active IP Right Cessation
- 2014-10-27 PH PH12014502407A patent/PH12014502407B1/en unknown
- 2014-10-29 CO CO14239767A patent/CO7170181A2/es not_active Application Discontinuation
- 2014-11-03 CL CL2014002979A patent/CL2014002979A1/es unknown
-
2015
- 2015-04-28 HK HK15104088.8A patent/HK1203399A1/xx not_active IP Right Cessation
-
2016
- 2016-04-26 US US15/138,570 patent/US9782396B2/en not_active Expired - Fee Related
- 2016-12-05 HR HRP20161634TT patent/HRP20161634T1/hr unknown
-
2017
- 2017-01-31 CY CY20171100139T patent/CY1118570T1/el unknown
- 2017-02-08 SM SM201700086T patent/SMT201700086B/it unknown
- 2017-09-11 US US15/701,300 patent/US20180214437A1/en not_active Abandoned
-
2018
- 2018-10-25 HR HRP20181761TT patent/HRP20181761T1/hr unknown
- 2018-11-05 CY CY181101154T patent/CY1120820T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161634T1 (hr) | Novi pripravak alfentanila za liječenje akutne boli | |
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| JP5841151B2 (ja) | 鼻腔噴霧剤 | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| JP2014517825A5 (hr) | ||
| JP2015513309A5 (hr) | ||
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| JP2011511793A5 (hr) | ||
| WO2013138628A3 (en) | Injectable ibuprofen formulation | |
| JP2012502047A5 (hr) | ||
| JP2017533972A5 (hr) | ||
| JP2015527321A5 (hr) | ||
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| JP2020500864A5 (hr) | ||
| NZ617397A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| JP2013541583A5 (hr) | ||
| JP2015515974A5 (hr) | ||
| JP2016512247A5 (hr) | ||
| JP2013520448A5 (hr) | ||
| Haghighat et al. | The effectiveness of GECB pastille in reducing complications of dry socket syndrome | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| TW201739448A (zh) | 用於治療及/或預防血液相關疾病之方法及配方 |